Compare GKOS & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | EAT |
|---|---|---|
| Founded | 1998 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.0B |
| IPO Year | 2015 | N/A |
| Metric | GKOS | EAT |
|---|---|---|
| Price | $116.08 | $150.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 16 |
| Target Price | $125.54 | ★ $165.00 |
| AVG Volume (30 Days) | 865.8K | ★ 1.5M |
| Earning Date | 10-29-2025 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.76 |
| EPS | N/A | ★ 9.64 |
| Revenue | $469,820,000.00 | ★ $5,594,400,000.00 |
| Revenue This Year | $31.15 | $7.80 |
| Revenue Next Year | $24.15 | $5.17 |
| P/E Ratio | ★ N/A | $15.49 |
| Revenue Growth | ★ 30.38 | 23.18 |
| 52 Week Low | $73.16 | $100.30 |
| 52 Week High | $163.71 | $192.22 |
| Indicator | GKOS | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 76.42 | 64.92 |
| Support Level | $105.88 | $143.52 |
| Resistance Level | $116.72 | $154.83 |
| Average True Range (ATR) | 3.26 | 6.46 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 94.61 | 79.71 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.